The United Kingdom and the United States have hammered out a key commercial pact that will ensure zero tariffs on British drug shipments going into the US market.
The Terms of the Accord
Under the terms of the agreement, the UK has agreed to raise funding on medicines through the National Health Service (NHS). This pledge ensures that tariffs on these crucial products will remain at zero for a period of the next three years.
This development comes after recent threats to significantly raise tariffs on patented pharmaceutical imports, with increases discussed reaching 100%.
"This agreement with the United Kingdom reinforces the international landscape for innovative medicines and establishes much-needed fairness to U.S.–U.K. drug exports," an announcement said.
Economic Importance
Drugs are one of the the United Kingdom's most significant export categories to the US, which is easily the largest buyer for major companies like GSK and AstraZeneca.
Statistics indicate that in the 12 months leading up to the third quarter, the UK exported drugs totaling £11.1bn to the US. This value represented nearly one-fifth of British export trade in that span.
"This deal safeguards jobs, increases investment and paves the way for the UK to establish itself as a worldwide center for medical research," a government official stated.
Specific British Pledges
The agreement entails several key pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the affordability limit at which it considers new medicines to be too expensive by twenty-five percent.
- Higher Drug Budget: There is a target to double overall NHS spending on treatments from 0.3% of Gross Domestic Product to 0.6% over the following ten-year period.
- Refund Ceiling: The percentage manufacturers must pay back to the NHS to stay within budget will be capped at 15%. Previously, repayments topped twenty percent.
Recent Tensions
The deal follows a long-running row between the drug companies and the UK government over drug pricing and NHS adoption.
These tensions were heightened by claims that US patients were paying several times more for the equivalent treatments than patients in the other developed nations.
In recent months, several major pharmaceutical investments in the UK have been halted or cancelled, while major funding commitments have been announced toward American operations.
One official publicly accepted that the NHS must increase expenditure on medicines, noting that its spending on drugs had shrunk as a proportion of its total funding over the past decade.
